Literature DB >> 479634

The determination of lipids and proteins in suction blister fluid.

B J Vermeer, F C Reman, C M van Gent.   

Abstract

The concentration of 5 different proteins in suction blister fluid and serum was determined by immunotechniques. These proteins, varying in size and molecular weight (6,600-2,300,000) were insulin, albumin, high density lipoprotein determined as apoprotein A-I, alpha 2-macroglobulin and low density lipoprotein measured as apoprotein B. The difference in the blister fluid/serum concentration ratio of the proteins was dependent on the molecular weight and followed mainly the law of diffusion. Moreover, the amounts of insulin, albumin and apoproteins A-I and B in suction blister fluid were the same as those reported in peripheral lymph. The results indicate that the sieve function of the capillary basement membrane remains intact during the formation of the suction blisters. Suction blister fluid might therefore be regarded as representative of interstitial fluid. The concentrations of 4 different lipids (cholesterol, cholesterolesters, triglycerides and phospholipids) were also determined and their blister fluid/serum concentration ratio proved to have a fairly constant value of 0.25.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479634     DOI: 10.1111/1523-1747.ep12531833

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  29 in total

Review 1.  Accessing analytes in biofluids for peripheral biochemical monitoring.

Authors:  Jason Heikenfeld; Andrew Jajack; Benjamin Feldman; Steve W Granger; Supriya Gaitonde; Gavi Begtrup; Benjamin A Katchman
Journal:  Nat Biotechnol       Date:  2019-02-25       Impact factor: 54.908

2.  Alpha-thiolproteinase inhibitor, alpha 1-antitrypsin and serum proteins in suction blister fluid; effect of local glucocorticosteroid treatment.

Authors:  U Kiistala; A Oikarinen; M Järvinen; A Ruokonen
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

3.  Passive drug diffusion via standardized skin mini-erosion; methodological aspects and clinical findings with new device.

Authors:  P Svedman; S Lundin; P Höglund; C Hammarlund; C Malmros; N Pantzar
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

4.  Plasma and suction blister fluid levels of etretinate and its main metabolite during treatment of psoriasis.

Authors:  J Lauharanta; U Paravicini
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

5.  Human plasma and skin blister fluid levels of griseofulvin following a single oral dose.

Authors:  M Schäfer-Korting; H C Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.

Authors:  Lucy Sasongko; Kenneth M Williams; Richard O Day; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

7.  Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis.

Authors:  Fiia P Gäddnäs; Meeri M Sutinen; Marjo Koskela; Taina Tervahartiala; Timo Sorsa; Tuula A Salo; Jouko J Laurila; Vesa Koivukangas; Tero I Ala-Kokko; Aarne Oikarinen
Journal:  Crit Care       Date:  2010-03-31       Impact factor: 9.097

8.  Determination of 8-methoxypsoralen levels in plasma and skin suction blister fluid by a new sensitive fluorodensitometric method.

Authors:  H C Korting; M Schäfer-Korting; E Roser-Maass; E Mutschler
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

9.  In vivo skin penetration of acitretin in volunteers using three sampling techniques.

Authors:  C Surber; K P Wilhelm; D Bermann; H I Maibach
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

10.  Cefodizime penetration into skin suction blister fluid following a single intravenous dose.

Authors:  M Schäfer-Korting; H C Korting; L Maass; N Klesel; H G Grigoleit; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.